Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.53 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.53 |
| ▸ | CTSK | P43235 | 12/20 | 0.51 |
| ▸ | CTSL | P07711 | 9/20 | 0.51 |
| ▸ | CTSS | P25774 | 7/20 | 0.51 |
| ▸ | CTSB | P07858 | 5/20 | 0.51 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | PREP | P48147 | 2/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | TDO2 | P48775 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23295570 | 0.87 | CTSK (0.54) | ITGB3ITGA2BCTSKCTSLCTSS | |
| SCHEMBL23295571 | 0.87 | CTSK (0.54) | ITGB3ITGA2BCTSKCTSLCTSS | |
| SCHEMBL25889247 | 0.86 | YAP1 (0.52) | ITGB3ITGA2BCTSKCTSLCTSS | |
| SCHEMBL30405428 | 0.84 | BCHE (0.48) | ITGB3ITGA2BCTSKCTSLCTSS | |
| SCHEMBL3005103 | 0.83 | CTSK (0.44) | ITGB3ITGA2BCTSKCTSLCTSS | |
| SCHEMBL3005100 | 0.83 | CTSK (0.44) | ITGB3ITGA2BCTSKCTSLCTSS | |
| SCHEMBL25282429 | 0.83 | CTSK (0.65) | ITGB3ITGA2BCTSKCTSLCTSS | |
| SCHEMBL25282430 | 0.83 | CTSK (0.65) | ITGB3ITGA2BCTSKCTSLCTSS | |
| SCHEMBL22122405 | 0.83 | CTSK (0.62) | ITGB3ITGA2BCTSKCTSLCTSS | |
| SCHEMBL15649121 | 0.83 | CTSK (0.62) | ITGB3ITGA2BCTSKCTSLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2152664-B1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-09-03 | — | — | EP | disclosed |
| US-8367709-B2 | Dipeptide analogs as coagulation factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-05 | — | — | US | disclosed |
| US-20100173899-A1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-07-08 | — | — | US | disclosed |
| EP-2152664-A1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | Brystol-Myers Squibb Company (US) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008157162-A1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173899-A1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | F11, TFPI, SERPINC1 | ITGB3 3113/4885ITGA2B 3709/4885CTSK 280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.